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Germline mutations that inactivate BRCA2 promote
early-onset cancer with chromosome instability.
Here, we report that BRCA2 regulates the spindle
assembly checkpoint (SAC). Previously, we reported
that BubR1 acetylation is essential for SAC activity.
In this study we show that BRCA2 recruits the
PCAF acetyltransferase and aids in BubR1 acetyla-
tion during mitosis. In the absence of BRCA2,
BubR1 acetylation is abolished, and the level of
BubR1 decreases during mitosis. Similarly, Brca2-
deficient mouse embryonic fibroblasts exhibited
weak SAC activity. Transgenic mice that were engi-
neered to have interruptions in the BRCA2-BubR1
association exhibited marked decrease of BubR1
acetylation, weakened SAC activity, and aneuploidy.
These transgenic mice developed spontaneous
tumors at 40% penetrance. Moreover, immunohisto-
chemical analyses of human breast cancer speci-
mens suggested that BRCA2 mutation and BubR1
status is closely linked. Our results provide an expla-
nation for how mutation of BRCA2 can lead to chro-
mosome instability without apparent mutations in
SAC components.
INTRODUCTION
BRCA2-deficient tumors exhibit chromosome instability, mani-
fested by aneuploidy with chromosome translocations (Lee
et al., 1999; Venkitaraman, 2002). Spontaneous translocation
and radially structured chromosomes arise due to a loss of regu-
lating Rad51 during homologous recombination (HR) and repair
(Pellegrini and Venkitaraman, 2004; Venkitaraman, 2002; West,
2003), consistent with the finding that BRCA2 is also FANCD1,
the gene mutated in the Fanconi anemia (Hirsch et al., 2004;
Howlett et al., 2002).DevelopmCompared to the involvement of BRCA2 in HR and the basis of
chromosome structure instability, the molecular mechanisms
underlying the chromosome number instability of BRCA2-defi-
cient cells are not as well understood. A number of studies report
a direct role of BRCA2 at the cytokinetic midbody (Daniels et al.,
2004; Lee et al., 2011), suggesting that the tumor-suppressive
function of BRCA2 is not restricted to regulation of DNA repair
but involves correct cell division. Failure of cytokinesis (comple-
tion of cell division) results in binucleated cells and polyploidy,
as has been observed in the Brca2-inactivated mouse model
(Rowley et al., 2011). Although cytokinetic failure can eventually
contribute to aneuploidy, unequal segregation of duplicated
chromosomes is the major cause of aneuploidy, particularly
the early-onset aneuploidy. Therefore, we hypothesized that
disruption of BRCA2 may directly interfere with proper chromo-
some segregation and contribute to aneuploidy.
Mitotic fidelity, the accurate segregation of chromosomes, is
guaranteed by the spindle assembly checkpoint (SAC). The
SAC ensures that each daughter cell receives the full comple-
ment of chromosomes after cell division by checking that all
chromosomes are attached with spindles in a bipolar manner
(Yu, 2002). From the unattached kinetochore a diffusible ‘‘wait
anaphase’’ signal is generated and amplified (Kulukian et al.,
2009). Ultimately, the SAC inhibits APC/C E3 ligase activity,
and the proteolysis of cyclin B is delayed. When the checkpoint
fails, cells either die or become aneuploid (Rieder and Maiato,
2004). In prometaphase, BubR1 recycles rapidly between kinet-
ochore and cytosol, binds to both APC/C and its coactivator
Cdc20, is a potent inhibitor of APC/C (Peters, 2006), monitors
chromosome spindle attachments (Ditchfield et al., 2003;
Lampson and Kapoor, 2005), and regulates mitotic timing
(Choi et al., 2009; Meraldi et al., 2004). Previously, we reported
that BubR1 is acetylated by PCAF acetyltransferase at prometa-
phase and that the acetylated BubR1 inhibits APC/C. When
checkpoint is satisfied, BubR1 is deacetylated and becomes
a substrate of APC/C-Cdc20 (Choi et al., 2009; Yekezare and
Pines, 2009).
In yeast two-hybrid screens, BRCA2 was found to bind to
BubR1 (Futamura et al., 2000). However, the physiological
outcome of the BRCA2-BubR1 interaction remains unclear.ental Cell 22, 295–308, February 14, 2012 ª2012 Elsevier Inc. 295
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Figure 1. BRCA2 Forms a Complex with BubR1 in Prometaphase
(A) HeLa cells transfected with indicated siRNAs were synchronized by double-thymidine block and released. Cells were harvested at the indicated time points
after release and subjected to IP with a BRCA2 antibody (sh-hB2-4, Figure S1E) and WB with BubR1 and BRCA2 antibodies (Calbiochem, Ab-1). TCLs (2.5%)
were subjected to WB with the indicated antibodies. WB with anti-Mad2 was included to control for off-target effects of siRNA.
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BRCA2 Regulates BubR1 AcetylationInterestingly, in vitro studies have suggested that the N terminus
of BRCA2 binds to PCAF (Fuks et al., 1998). Together, we
hypothesized that BRCA2 may be involved in the process of
BubR1 acetylation in mitosis by serving as a scaffold for interac-
tion between PCAF and BubR1. Here, we show that BRCA2
recruits PCAF and mediates the association and acetylation of
BubR1; BRCA2 is involved in proper control of mitosis. This
study reveals the role of BRCA2 in chromosome segregation
and provides an explanation for aneuploidy in BRCA2-deficient
cells.
RESULTS
BRCA2 Associates with BubR1 in Prometaphase
To elucidate the mitotic role of BRCA2, we first confirmed the
physical association between BRCA2 and BubR1. The results
indicated that BRCA2 andBubR1 form a complex duringmitosis,
12 hr after thymidine release, as shown by the levels of cyclin B
and phospho-histone H3 (pH3) (Figure 1A).
We generated a series of deletion mutants to map the interac-
tion domains (Figure 1B) and found that the N terminus (amino
acids 1–514) of BubR1, the region essential for its checkpoint
activity (Malureanu et al., 2009), physically interacts with the
extreme C terminus of BRCA2 (amino acids 3,189–3,418;
Figures 1B–1D; see Figure S1 available online). This region of
BRCA2 is involved in the stability of oligomerized Rad51 fila-
ments (Davies and Pellegrini, 2007) and contains CDK1 phos-
phorylation sites (Esashi et al., 2007).
Next, we determined the timing of BRCA2/BubR1 complex
formation during mitosis. HeLa cells were synchronized at prom-
etaphase by nocodazole (Noc) treatment, released into the
mitotic cell cycle, and subjected to immunoprecipitation (IP)
and western blotting (WB). Importantly, BubR1 was detected
only in BRCA2 immune complex of Noc-arrested cells (Fig-
ure 1E), indicating that BRCA2/BubR1 complex forms predomi-
nantly during prometaphase. Notably, BRCA2-bound BubR1
was acetylated, as detected byWB results using an AcK250 anti-
body (Figure 1E, aAcK250) (Choi et al., 2009).
BubR1 localizes to kinetochores, where it ensures bipolar
spindle attachments and is involved in checkpoint signaling(B) Schematic illustration of the various BRCA2-deletion (upper panel; see also F
reported are marked. BRCA2 deletion constructs were tagged with GFP or GST
(C) A series of GST-fused BRCA2 deletion mutants were purified from E. coli.
Sepharose 4B beadswas incubatedwith in vitro-translated and 35S-labeled BubR
the recombinant proteins in the reaction (upper panel). The mapping of the Bu
followed by IP (anti-GFP) and WB analyses (9E10). The same blot was reprobed
(D) Two micrograms of GST-B2-9 (BubR1-interacting BRCA2 C terminus) were i
(E) BRCA2 and BubR1 interact in mitosis. HeLa cells were synchronized with N
assessed by flow cytometry (right). At the indicated times, cells were harvested a
BRCA2 (Ab-1) and anti-AcK250. Lysates from attached cells (Attach) served as a
(F) BRCA2 colocalizes with BubR1 at prometaphase kinetochores. Metaphase ch
BRCA2 (Calbiochem, Ab-2), and anti-BubR1 or anti-Aurora B. Photographs were
images of single chromosomes in each setting are shown (lower panel). Scale b
(G) Kinetochore localization of BRCA2 was confirmed in HeLa cells expressing
images of single chromosomes are shown (right panel). Scale bar, 5 mm.
(H) Cytosolic BubR1 mutant also interacts with BRCA2 and is acetylated. 293T
-K250R, -K250Q, -E413K) and BRCA2 encoding plasmids. K250Q is the acetyla
et al., 2009). Cells kept in mitosis with Noc and MG132 treatment were subjected
Neg, negative control. See also Figure S1.
Developm(Elowe et al., 2007; Logarinho and Bousbaa, 2008). Therefore,
we first assessed whether the BRCA2-BubR1 complex was
present at the prometaphase kinetochore. In chromosome
spreads coupled with immunofluorescence, we observed that
BRCA2 was associated with BubR1 at the outer kinetochores
(Figure 1F, red box). By contrast, Aurora B, which localizes to
the inner centromeres (Vagnarelli and Earnshaw, 2004), did not
overlap with BRCA2 (Figure 1F, green box).
To exclude the possibility that the BRCA2 antibody detected
the kinetochore nonspecifically, BRCA2 localization was exam-
ined in HeLa cells expressing full-length bacterial artificial chro-
mosome (BAC)-encoded N terminus FLAP-tagged BRCA2
(NFLAP-BRCA2) (Lekomtsev et al., 2010). The result showed
that approximately 47% of green fluorescent protein (GFP)
fluorescence overlapped with CREST immunofluorescence
(Figure S1D). In chromosome spreads coupled with immunoflu-
orescence, BRCA2 colocalization with BubR1 was confirmed
(Figure 1G).
BRCA2 binding to BubR1 was not restricted to the kineto-
chores because the cytosolic BubR1 mutant E413K that retains
the ability to inhibit APC/C-Cdc20 (Malureanu et al., 2009) could
bind to BRCA2 (Figures 1H and S1C). E413Kwas also acetylated
in prometaphase (Figure 1H, AcK250). Collectively, these data
led us to hypothesize that BRCA2 participates in a regulatory
pathway involving BubR1 acetylation and SAC activity.
BRCA2 Is Required for BubR1 Acetylation
The failure of BubR1 acetylation results in premature degrada-
tion of BubR1 in prometaphase and shortened mitotic timing
(Choi et al., 2009). To address whether BRCA2 is involved in
BubR1 acetylation, we analyzed mitotic BubR1 levels in HeLa
cells transfected with siRNAs against BRCA2. The results
indicate that the level of BubR1, but not that of Bub1, was mark-
edly decreased at prometaphase kinetochores, when BRCA2
was depleted (Figure 2A). The decrease in BubR1 levels at
kinetochores fits with the elevated levels of ubiquitination and
subsequent degradation of BubR1 when BRCA2 is depleted
(Figure 2B). Consistently, BubR1 acetylation at K250 was mark-
edly reduced after silencing BRCA2 (Figure 2B, AcK250), which
was restored upon expression of FLAG-BRCA2 (Figure S2A).igure S1A) and BubR1-deletion constructs (lower panel). The functional motifs
, and BubR1 deletion constructs were myc tagged at the N terminus.
One microgram of each recombinant BRCA2 GST-fusion protein bound to
1 (Myc tagged) and analyzed. A Ponceau S-stained blot is included to normalize
bR1-interacting BRCA2 domain was confirmed by transfection in 293T cells
with anti-GFP (lower panel).
ncubated with a series of 35S-labeled BubR1 deletion mutants and analyzed.
oc and mitotic shake off, and then were released. The cell-cycle profile was
nd subjected to IP with anti-BRCA2 (sh-hB2-4) and WB with anti-BubR1, anti-
n interphase control. Neg, negative control.
romosome spreads from HeLa cells were coimmunostained with CREST, anti-
taken at 1,0003 magnification under a DeltaVision RT microscope. Enlarged
ar, 5 mm.
BAC-encoded GFP-BRCA2. BRCA2 was detected with anti-GFP. Enlarged
cells were cotransfected with Myc-tagged BubR1 mutants (Myc-BubR1 WT,
tion-mimetic form and K250R is the acetylation-deficient form of BubR1 (Choi
to IP with 9E10 and WB with anti-BRCA2 (Ab-1), -PCAF, -Bub3, and -AcK250.
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Figure 2. BRCA2 Is Required for PCAF-Mediated BubR1 Acetylation
(A) HeLa cells transfected with indicated siRNAs were subjected to coimmunostaining with CREST and anti-BubR1 or anti-Bub1. Prometaphase cells are
presented. Scale bar, 5 mm.
(B) HeLa cells transfected with two different siRNAs against BRCA2 were Noc arrested and treated with MG132 then subjected to IP with a BubR1 antibody and
WB with the indicated antibodies (in B, C, and F, anti-BRCA2 [Calbiochem, Ab-1] was used). The intensities of BubR1 and AcK250 were measured using the
densitometer (Multi Gauge), and the ratio of AcK250/total BubR1 in each lane, relative to siControl, is marked.
(C) HeLa cells transfected with indicated siRNAswere treatedwith the drugs indicated. The levels of each protein in anti-PCAF immunoprecipitates and TCLwere
analyzed by WB. Numbers at the bottom indicate the ratio of AcK250/total BubR1 in each lane, relative to the siControl.
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BRCA2 Regulates BubR1 AcetylationThese data suggest that BRCA2 contributes to regulation of
BubR1 acetylation.
Next, we asked howBRCA2 participates in BubR1 acetylation.
BRCA2 does not possess innate acetyltransferase activity (Fig-
ure S2B). Therefore, we tested whether BRCA2 affected the
association between PCAF and BubR1. We examined PCAF
immune complexes in HeLa cells transfected with siRNAs
against BRCA2 and compared them with those of the control.
In control cells PCAF and BubR1 binding, and BubR1 acetyla-
tion, was detected exclusively in mitosis, i.e., in Noc-arrested
cells and in cells treated with Noc followed byMG132 (Figure 2C,
siControl). In comparison, BubR1 disappeared from PCAF
immune complexes when cells were depleted of BRCA2 (Fig-
ure 2C, siBRCA2). Consistently, BubR1 acetylation was de-
tected in total cell lysates (TCLs) of control mitotic cells, but
not in cells depleted of BRCA2 (Figure 2C, aAcK250). IP with
an AcK250 antibody and WB with a PCAF or BubR1 antibody
gave consistent results (Figure S2C), suggesting that BRCA2 is
required and may serve as a scaffold for the binding of BubR1
and PCAF during prometaphase.
To confirm that BRCA2 serves as a platform for PCAF-BubR1
binding, we measured the protein levels at the kinetochore
(Figures 2D–2F). Knockdown of BRCA2 by siRNA resulted in
a 4-fold reduction in BubR1 and PCAF levels (Figures 2D, 2E,
S2D, and S2E, siBRCA2). Depletion of PCAF resulted in a similar
level of BubR1 reduction (Figures 2D, 2E, S2D, and S2E,
siPCAF); however, the BRCA2 level was unchanged when
PCAF was depleted (Figures 2D and 2E, siPCAF). The reduction
in BubR1 levels after depletion of BRCA2 or PCAF was restored
when cells were treated with MG132 at the kinetochore and in
whole cell (Figures S2F and S2G), indicating that the reduction
resulted from proteolysis, and not the failure in localization at
the kinetochore.
The requirement of BRCA2 in BubR1 acetylation and mainte-
nance in prometaphase was confirmed in mouse embryonic
fibroblasts (MEFs) isolated from Brca2 (mouse BRCA2)-condi-
tional knockout mice. When the Brca2 allele was disrupted in
Brca2f11/f11 MEFs (Jonkers et al., 2001) after infection with an
adenovirus expressing Cre recombinase (Ad-Cre), the levels of
BubR1 markedly decreased in prometaphase, whereas Bub1
was unchanged (Figure 2G). In Brca2f11/f11 MEFs, exon 11 is
deleted, but others are expressed in frame (Figure 2H) (Jonkers
et al., 2001). Therefore, this result suggests that in addition to
the BubR1-binding C terminus (Figures 1 and S1) and the
N-terminal PCAF-binding domains (Fuks et al., 1998), the
domain encoded by exon 11 of Brca2 is required for BubR1 to
be properly acetylated and maintain adequate levels at the
prometaphase kinetochore.(D) HeLa cells transfected with indicated siRNAs were treated with 100 ng/ml N
spreads were prepared, followed by immunostaining with anti-BRCA2 (Calbioch
(E) Fluorescence intensity at kinetochores (D) was measured using ImageJ and
(mean ± SEM; nR 5 prometaphase cells: siControl [n = 1,524 kinetochores]; siBR
the siControl calculated by a t test (p < 0.0001).
(F) WB to assess the efficiency of each siRNA used in (D) and (E). Lysates from a
(G) The level of BubR1 at kinetochores in Brca2-conditional knockout MEFs. B
Brca2f11/f11 48 hr after infection with 100 MOI of GFP (Cre) or Cre (+Cre)-expre
(H) Knockdown efficiency by Ad-Cre infection in (G). Brca2 was analyzed by WB w
(Cre) or Ad-Cre (+Cre) infection. Intact Brca2 is lost after Ad-Cre infection, and a
predicted size of truncated Brca2 in the Brca2f11/f11 allele. Lamin A/C served as
DevelopmBRCA2 Controls SAC Activity by Regulating BubR1
Acetylation
Next, we examined the contribution of BRCA2 in SAC activity.
First, we assessed the response to microtubule poisoning by
measuring the mitotic index; that is the proportion of cells ar-
rested in mitosis upon Noc treatment. The mitotic index was
determined by measuring the number of 4C cells that finished
replication and were positive for mitotic protein monoclonal 2
(MPM2) immunostaining, which specifically detects phospho-
proteins in mitosis (Davis et al., 1983). Twenty-four hours post-
Noc treatment, approximately 68% of HeLa cells exhibited
MPM2 positivity, indicating that the SAC was intact (Choi et al.,
2009; Davis et al., 1983) (Figure 3A, siControl, blue diamonds).
In contrast, BubR1-depleted cells lost the typical MPM2 peak
following Noc treatment, indicating that their SAC was compro-
mised (Figure 3A, siBubR1, green triangles). Cells transfected
with siRNAs against BRCA2 exhibited markedly less MPM2
staining compared with control cells, indicating weakened SAC
activity (Figure 3A, siBRCA2, red rectangles).
Because BRCA2 plays crucial roles in double-stranded DNA
break repair, depleting BRCA2 results in DNA damage that might
interfere with entry into mitosis. We checked the cell-cycle
profiles at the time of SAC analysis. The result showed that
depleting BRCA2 did not change the cell-cycle profile in our
experimental setting (Figure S3C). Analysis of g-H2AX staining
(Figures S3D and S3E) and metaphase chromosomes (Fig-
ure S3H, lower panel) also indicated that DNA damage was not
significant at 48 hr post-BRCA2 depletion. These results suggest
that the weakened SAC activity in BRCA2-depleted cells is not
the secondary effect from impaired mitotic entry.
To confirm the result, we assessed the SAC activity by count-
ing the number of 50 bromodeoxyuridine (BrdU)-positive mitotic
cells (pH3 positive) after BrdU pulse and Noc treatment (Jeong
et al., 2010) (Figures 3B and S3A). Up to 80% of mitotic cells
were BrdU-positive at 15.5 hr post-Noc treatment, which
decreased at 21.5 hr, a pattern similar to MPM2 staining. In
comparison, cells depleted of BubR1 or BRCA2 displayed
dramatic decrease of BrdU-positive mitotic cells. This result
confirms that the absence of BRCA2 weakens SAC activity
(Figures 3B, S3A, and S3B).
In an accompanying experiment, micronuclei were frequently
observed in BubR1- and BRCA2-depleted cells, which
increased with time after Noc treatment (Figure 3C). These
data suggest that, similar to BubR1-depleted cells, BRCA2-
depleted cells display failures in accurate chromosome segrega-
tion and mitotic infidelity.
Next, we assessed the mitotic timing in MEFs derived from
Brca2 conditional knockout mice (Jonkers et al., 2001). MEFsoc for 6 hr, subjected to mitotic shake off, and the metaphase chromosome
em, Ab-2), anti-BubR1, and anti-PCAF antibodies. Scale bar, 5 mm.
depicted as histograms. The results are from two independent experiments
CA2 [n = 1,089]; siPCAF [n = 294]). Asterisks mark significant differences from
ttached cells (out of mitotic shake off) were analyzed.
ub1 and BubR1 levels in prometaphase kinetochores were each assessed in
ssing adenovirus. Scale bar, 5 mm.
ith an anti-mouse Brca2 antibody (sh-mB2-9, Figure S1E), 48 hr after Ad-GFP
faster migrating band (asterisk) is detected instead, which corresponds to the
a loading control. See also Figure S2.
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Figure 3. BRCA2 Is Involved in the Regulation of SAC Activity
(A) Responses to Noc by measuring the mitotic indices after Noc treatment in control, BRCA2-depleted, or BubR1-depleted HeLa cells. HeLa cells were
transfected twice with siRNA for GFP, BRCA2, or BubR1 at 24 hr intervals. Cells were then exposed to 200 ng/ml Noc, and aliquots of cells were collected at the
indicated times. They were then subjected toMPM2 immunostaining and propidium iodide (PI) staining. The percentage of cells positive for MPM2with 4CDNA is
marked on the y axis, and the time after Noc treatment on the x axis. The efficiency of each siRNA was assessed (right panel).
(B) SAC activity was measured by BrdU pulse-chase and scoring of mitotic cells after Noc treatment. Thirty-six hours after transfection of indicated siRNAs in
HeLa cells, they were incubated with 10 mMBrdU for 2.5 hr, washed, and treated with Noc. Cells were fixed at the indicated time points and immunostained with
anti-BrdU and anti-pH3. BrdU-positive, pH3-positive cells were scored and depicted as histograms. x axis, time after Noc treatment; y axis, percentage of BrdU-
positive/pH3-positive mitotic cells. Asterisks mark the significant p values (p < 0.0001) when compared to the cells transfected with control siRNA.
(C) Marked increase of micronuclei in BRCA2-depleted or BubR1-depleted HeLa cells. Micronuclei were detected by DAPI staining. The results are from two
independent experiments (mean ± SEM; nR 200 BrdU-positive cells).
(D and E) MEFs from Brca2-conditional knockout mice were infected with GFP- (Cre) or Cre-expressing adenovirus (+Cre) and subjected to live imaging in the
presence or absence of Noc treatment. Recording started 36 hr postinfection and continued for 18 hr. (D) Box plot distributions of statistical mitotic timing from
NEBD to anaphase onset. Without Noc treatment, mitosis required average 25 min in Ad-GFP infected MEFs (Cre, n = 242) and approximately 17 min in Brca2-
deficient MEFs (+Cre, n = 168) (Noc). When cells were exposed to Noc during recording, control MEFs (Cre, n = 74) stayed in mitosis for over 500 min. Brca2-
deficient MEFs (+Cre, n = 86) exited from mitosis (chromosome decondensation) within 267 min (+Noc). Bars in the box represent median values. Outliers (open
circle) and suspected outliers (asterisk) as determined by statistical analysis are marked. (E) Representative images captured at the indicated time points from (D)
without Noc. Note the lagging chromosomes and anaphase bridges in Ad-Cre-infected MEFs. The timing of NEBD is set to 00:00. Scale bar, 5 mm.
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BRCA2 Regulates BubR1 Acetylationfrom Brca2f11/f11mice were infected with adenovirus expressing
GFP (Ad-GFP) or Ad-Cre, and then were either challenged or left
unchallenged with Noc and subjected to time-lapsemicroscopy.
Elapsed time from nuclear envelope breakdown (NEBD) to
anaphase onset (Noc) or mitotic exit (+Noc) was measured.
The duration of mitosis in untreated cells was approximately
8 min shorter in Brca2-deficient MEFs (Figure 3D, Ad-Cre,
Noc; Movies S2 and S3) than in control MEFs (Figure 3D, Ad-
GFP; Noc; Movie S1). Upon Noc treatment the difference
became more profound; control MEFs (Ad-GFP) were arrested
in mitosis for approximately 9 hr (Figure 3D, +Noc), whereas
Brca2-depleted MEFs (Ad-Cre) were in mitosis for less than
5 hr (Figure 3D, +Noc). Lagging chromosomes and premature
chromosome segregation without congression were frequently
observed (57%, n = 96) in Brca2-deficient MEFs even without
a Noc challenge (Figure 3E, +Cre). These are unlikely to be the
secondary effects from DNA damage because no noticeable
difference in the cell-cycle profile (Figure S3F), g-H2AX staining
(Figure S3G), or chromosome aberrations was observed (Fig-
ure S3H) at the time of analysis. Six days after Ad-Cre infection
in Brca2f11/f11 MEFs, radial-structured chromosomes resulting
from impaired HR were observed. Together, these results
support that BRCA2 contributes to the intactness of SAC and
mitotic fidelity.
We reasoned that if BRCA2 is involved in BubR1 acetyla-
tion and SAC control, ectopic expression of an acetylation
mimetic form of BubR1 should, at least in part, restore the
weakened SAC of BRCA2-deficient cells. An acetylation
mimetic form of BubR1 is created when K250 is substituted
with glutamine (K250Q), whereas a lysine-to-arginine substitu-
tion prevents acetylation (Choi et al., 2009). Using these prop-
erties, we coinfected Brca2f11/f11 MEFs with Ad-GFP-BubR1
(WT), -K250R, or -K250Q, with Ad-GFP or Ad-Cre, and then
measured the response to Noc as in Figure 3B. We observed
that K250Q expression (Ad-K250Q), but not K250R or even
WT expression, recovered the ability of Brca2-depleted
MEFs (+Cre) to arrest in mitosis in response to microtubule
poisoning to a level comparable to Brca2-positive MEFs
(Cre; Figure 3F).
We then measured the protein levels after transfection of
Brca2f11/f11 MEFs with DsRed-tagged BubR1 constructs. Only
the acetylation-mimetic BubR1-K250Q produced adequate
levels of BubR1 at prometaphase kinetochores in Brca2-defi-
cient MEFs, whereas K250R and the wild-type (WT) did not
(Figures 3G and 3H). When proteolysis was blocked by
MG132 addition, the fluorescence intensity of the WT and
K250R was restored both at the kinetochore and cytosol
(Figures 3H and S3I). The insufficient level of WT BubR1 in
Brca2-deficient MEFs suggests that BRCA2-involved BubR1
acetylation is critically required for the stability of BubR1 in
prometaphase.(F) Brca2f11/f11 MEFs were coinfected with Ad-Cre together with WT-, K250R-, o
points were assessed by measuring the mitotic index as in (B). Data are from tw
(G and H) Brca2f11/f11 MEFs transfected with DsRed-tagged BubR1, -K250R, or
without (+Cre) Brca2 in the absence or presence of MG132. Immunostaining wi
Scale bar, 5 mm. (H) Quantification of the results in (G). The results are from two in
Figure S3.
DevelopmSpontaneous Cancer Development in Transgenic Mice
with Disrupted BRCA2-BubR1 Binding
To investigate the consequence of BRCA2-BubR1 binding
in vivo, we generated a transgenic mouse line that ectopically
expresses the BubR1-binding region (B2-9). Our rationale was
that the ectopically expressed B2-9 of Brca2 would interfere
with normal Brca2-BubR1 binding and decrease the mitotic
BubR1 acetylation (Figure 4A).
Mouse cDNA corresponding to the B2-9 region of Brca2
(amino acids 3,101–3,328) was engineered to be expressed in
all tissues (Figure 4B). After analyzing 74 offspring from the trans-
gene-injected mouse, we obtained only 2 germline-transmitted
founders (Figure S4), suggesting that mB2-9-overexpressing
embryos may not have survived to birth, and only the weak
expressers were born. The transgenic mice (hereafter referred
to as mB2-9 mice), which survived to birth, did not show
apparent developmental defects. The expression of the B2-9
fragment in these two founders was confirmed by WB analysis
in the thymus, brain, heart, and skin (Figure S4B).
At 71–90 weeks after birth, spontaneous tumor development
was observed in mB2-9 mice, including abdominal sarcomas,
cutaneous squamous cell carcinomas, gland adenocarcinomas,
and splenomegaly (Figures 4C–4F; Table 1). The incidence of
carcinomas and splenomegaly was much higher than that of
sarcomas (Figure 4D; Table 1). A low incidence of lung papillary
carcinomas in WT mice was observed, but this is because aged
FVB/N mouse strain develops spontaneous lung cancer (Mahler
et al., 1996). Overall, the tumor incidence was approximately
40% and 4-fold higher in mB2-9 mice (Figure 4E).
Further analyses of the splenomegalies in the mB2-9 mice
indicated that they were lymphoma and leukemia. In paraffin-
embedded sections it was observed that the spleens of mB2-9
micewere infiltrated bywhite blood cells, indicative of lymphoma
(Figure 4F). In subsequent cytogenetic and flow cytometric anal-
yses, we found that B220+ cells, marker of B lymphocytes,
increased dramatically, suggesting that B cell lymphomas had
developed in themB2-9mice (Figure 4G). We also found spleens
that were highly infiltrated by promyelocytes and/or megakaryo-
cytes; Mac-1high and Gr-1high cells increased dramatically in
mB2-9 splenomegaly (Figure 4H), indicating that either acute
myelocytic leukemia (Somervaille and Cleary, 2006) or chronic
myelocytic leukemia (Shim et al., 2003) developed in mB2-9
mice.
Importantly, cancers from mB2-9 transgenic mice showed
a high degree of genetic instability, as evaluated by comparative
genomic hybridization (CGH) analysis: the genomic profile of the
malignant soft cell tumor fluctuates severely at the chromosome
level, indicating that the genomic complexity is markedly
increased (Figure 4I).
We assessed whether ectopic expression of the BubR1-bind-
ing domain of Brca2 indeed interfered with normal Brca2-BubR1r K250Q-BubR1-expressing adenovirus. Responses to Noc at indicated time
o independent experiments (mean ± SEM; nR 2,084 cells).
-K250Q, respectively, and the red fluorescence were measured with (Cre) or
th CREST marks the kinetochore. (G) Representative images without MG132.
dependent experiments (mean ± SEM; nR 20 prometaphase cells). See also
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Figure 4. Development of Spontaneous Cancers and Lymphomas/Leukemias in mB2-9 Mice
(A) Hypothetical model predicting the status of BubR1 acetylation and SAC in mB2-9 transgenic mice.
(B) Diagram of the construct used to generate mB2-9 transgenic mice. Arrows denote PCR primer sites for genotyping (Figure S4A).
(C) Hematoxylin and eosin-stained (H&E) cancer tissue sections of mB2-9 mice. Abdominal sarcoma (a–c), cutaneous squamous cell carcinoma (d–f), and gland
adenocarcinoma (g–i), are shown.
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Table 1. Spectrum of Cancers in WT and mB2-9 Mice
WT
mB2-9
(Line 499)
mB2-9
(Line 500)
No. of animals (%) 53 (100) 18 (100) 31 (100)
Carcinoma 4 (7.5) 5 (27.8) 9 (29.0)
Sarcoma 2 (3.8) 2 (11.1) 3 (9.7)
Splenomegalya 1 (1.9) 2 (11.1) 7 (22.5)
a Spleens exhibited lymphocyte expansion and/or myelocyte infiltration,
indicative of lymphoma/leukemia.
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MEFs isolated from mB2-9 mice, whereas it was found in WT
(Figure 5A). Because the N terminus of BubR1 binds to Cdc20
(Malureanu et al., 2009), binding to Cdc20 was assessed. The
result showed that the binding between BubR1 and Cdc20
was not perturbed. Data from the activated splenocytes
confirmed the results (Figure S5A).
We then asked whether the levels of BubR1 and BubR1
acetylation were affected in mB2-9 mice. WB analysis of
MEFs revealed that the amount of BubR1 in interphase (Fig-
ure 5B, Noc) was not noticeably different. However, the
amount of BubR1 was markedly reduced in mB2-9 mice when
cells were treated with Noc (Figure 5B, +Noc). The levels of
Rad51, actin, and pH3 indicated that the numbers of cells
analyzed were similar. Notably, mitotic BubR1 acetylation was
decreased to half in mB2-9 MEFs, when compared to control
(Figure 5C). Consistently, the amount of PCAF bound to BubR1
was decreased (Figure 5C, aPCAF). Similar results were ob-
tained from the activated splenocytes (Figure S5B). Altogether,
these data suggest that the ectopic expression of B2-9 indeed
interfered with BRCA2-BubR1 binding and BubR1 acetylation.
We next examined the timing of mitosis in transgenic MEFs.
The timing from NEBD to anaphase onset was approximately
10 min shorter in mB2-9 MEFs than in WT without any treatment
(Figure 5D,Noc). When cells were challenged with Noc, mB2-9
MEFs exited from mitosis within approximately 300 min, as
judged by the decondensation of chromosomes, whereas
control MEFs were arrested in mitosis without dividing for
more than 400 min (Figure 5D, +Noc). These results suggest
that the function of BubR1 in mitotic timing and SAC activity is
at least partially compromised in mB2-9 cells. Because the
binding of BubR1-Cdc20 was not perturbed in mB2-9, the weak-
ened SAC is the result of perturbed BRCA2-BubR1 binding.
Finally, we analyzed metaphase chromosome spreads from
the MEFs. The result showed that mB2-9 MEFs at passage 3(D) Incidence of cancers in mB2-9 mice. Two different founder lines were analyze
diagnosed as lymphoma/leukemia in the experiments in (F)–(H).
(E) Tumor incidence in mB2-9 mice. Data were analyzed using SPSS software. p
test.
(F) mB2-9 mice develop lymphomas and/or leukemias. Splenomegaly in mB2-9
Spleens fromWTmice (b and c) displayed alternating red and white pulp, mainly c
were markedly enlarged, architecturally distorted, and infiltrated with atypical w
megakaryocytes (large cells, dashed circle in g). Insets in (e) and (g), magnified i
(G) Increase of the B220-positive B cell population to 2-fold in the spleens of mB
(H) Marked increase of the myelocyte cell population (high Mac-1 and high Gr-1
(I) Array CGH of WT tissue and malignant soft cell tumor from mB2-9 mouse. P
genomic position (x axis) were generated using CGH-Explorer software, followin
Developmalready exhibit chromosome number instability: 56% of cells ex-
hibited losses and gains of chromosomes (Figure 5E). Polyploidy
was rarely observed (Figure 5E).
The C terminus of Brca2 expressed in mB2-9 mice contains
the binding domain for Rad51 and a CDK1 phosphorylation
site (Esashi et al., 2005, 2007) involved in regulation of
HR. Because the C terminus is crucial in the stabilization of
Rad51 filaments (Davies and Pellegrini, 2007; Esashi et al.,
2007), we asked whether ectopic expression of B2-9 interfered
with DNA repair and synergized with weakened SAC in
tumorigenesis.
Cell-cycle profiles of WT and mB2-9 were similar before and
after irradiation (IR), indicating that the ectopic expression of
the B2-9 region did not interfere with the DNA damage response
to a significant level (Figure 5F). Consistently, the level of DNA
damage, assessed by g-H2AX staining (Figure 5G) or the
Rad51 foci formation (Figures 5H and S5C), was not significantly
different from that of the control. In the metaphase chromo-
somes, tri-radial and quadri-radial chromosomes, the hallmarks
of defective HR in Brca2 null cells (Patel et al., 1998), were not
found in mB2-9MEFs. Even after IR, we did not find radial-struc-
tured chromosomes. Only some chromatid breaks were found,
and importantly, the incidence was similar to that of the WT (Fig-
ure 5I). Finally, we asked whether the actual HR activity was
affected by employing DR-GFP recombination assay (Pierce
et al., 1999), using transient transfection in MEFs. Flow cytomet-
ric analysis of the GFP-positive cells, representing successful
HR (Figure S5D), indicated that the HR activity was not reduced
in mB2-9MEFs, compared to that of theWT (Figure 5J). Interest-
ingly, the binding affinity of BubR1 to B2-9 was markedly higher
compared to Rad51, and themutation of serine 3291 in B2-9, the
site phosphorylated by CDK1 and essential in Rad51 release
before mitosis (Esashi et al., 2005), did not interfere with
BubR1 binding as well (Figure S5E). These results support that
B2-9 expression interfered with BRCA2-BubR1 binding more
than Rad51-mediated HR.
Clinical Relevance: Reduced BubR1 Levels
in BRCA2-Mutated Breast Cancers
Our results indicate that the level of BubR1 in BRCA2-mutated
cancers may be associated with the status of BRCA2. To deter-
mine whether there is any clinical relevance for our results,
paraffin sections from breast cancer patient specimens (see
Table S1) were analyzed for BubR1 levels by immunohistochem-
istry (IHC). IHC staining usually detects BubR1 in cancer cells,
but not in surrounding normal tissues (Grabsch et al., 2003;
Lee et al., 2009; Yamamoto et al., 2007), indicating that BubR1d and compared with WT. Splenomegalies from mB2-9 transgenic mice were
Values represent a significant difference from WT according to Fisher’s exact
transgenic mice (a) were analyzed. H&E of paraffin-embedded spleens (b–g).
omposed of lymphocytes (small dark-blue cells). Spleens of mB2-9 mice (d–g)
hite blood cells (medium-sized and light-blue cells, dashed circle in e) and/or
mages of infiltrated cells.
2-9 mice.
) in the spleens of mB2-9 transgenic mice.
lots of copy number variations, the gain/loss frequencies (y axis), relative to
g the methods of Chin et al. (2006). See also Figure S4.
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Figure 5. mB2-9 Mice Exhibit Weak SAC Activity
(A) MEFs isolated from WT and mB2-9 mice were subjected to IP using anti-BubR1 and WB using anti-Brca2 (sh-mB2-9), anti-HA, or anti-Cdc20. WB in TCL
shows the input control (left panel).
(B) WB analysis of MEFs isolated from WT and mB2-9 siblings. Passage matched (at passage 4) WT and transgenic MEFs from two different founders were
incubated for 14 hr with or without 200 ng/ml Noc and subjected to WB with the indicated antibodies.
(C) BubR1 acetylation in mitosis is markedly reduced in mB2-9MEFs. Cells were treated with Noc, and the lysates were subjected to IP andWB as indicated. The
ratio of AcK243/ total BubR1, relative to the control, is marked underneath each lane.
(D) Timing fromNEBD to anaphase onset (Noc) or mitotic exit (+Noc) wasmeasured. Without Noc treatment the duration of mitosis was approximately 23min in
mB2-9 (n = 55) and 33 min in WT (n = 83), respectively (Noc). When cells were exposed to Noc during recording, WT MEFs (n = 26) were arrested in mitosis for
over 400 min. In comparison, mB2-9 (n = 25) exited from mitosis within 300 min (+Noc). The data are from two independent experiments.
(E) Aneuploidy in mB2-9 MEFs. The metaphase chromosome of WT (n = 108) and mB2-9 MEFs (n = 130) in passage 2 and 3 were analyzed. Chromosome
numbers are depicted as histograms. Note the significant reduction of cells with normal chromosome numbers (40) in mB2-9MEFs. The results of the histograms
are summarized as a table and shown in the bottom.
(F) Cell-cycle profiles with (+IR) or without (IR) IR (15 Gy). Cells were analyzed 18 hr post-IR.
(G) Comparison of DNA damage in WT and mB2-9 MEFs. Cells were stained with a g-H2AX antibody, and g-H2AX-positive cells were counted. Percentages of
g-H2AX-positive cells, in interphase (left) and in mitosis (right) as bar graphs. More than 2,000 cells each were scored. For scoring g-H2AX-positive mitotic cells
(with condensed chromosomes), 326 (WT) and 383 (mB2-9) cells were employed. Data are from two independent experiments without ectopic DNA damage
(mean ± SEM).
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BRCA2 Regulates BubR1 Acetylationpositivity, either mild or strong, reflects the high mitotic index of
cancers. We predicted that BubR1 levels would be lower in
BRCA2-mutated cancers than in cancers with intact BRCA2
because BubR1 acetylation would not be maintained during
proliferation. As expected, cancerous regions with high mitotic
indices were positive for BubR1 IHC (Figures 6B and 6D; table
in Figure 6E), whereas normal regions from the same specimens
were negative (Figures 6A and 6C). The score of BubR1 immuno-
staining (i.e., the sum of its intensity and distribution; see also
Experimental Procedures) was reduced in cancers with mutated
BRCA2 compared with those with intact BRCA2 (Figure 6E). The
BRCA2 mutations in the analyzed samples included those that
did not express the BubR1-binding domain. However, there
were also mutations that did not directly affect the BubR1-
binding domain (Table S1). We interpreted that the result is
in agreement with the data from Brca2f11/f11 MEFs: not only
the direct BubR1-binding C terminus or the PCAF-interacting
N terminus, but the entire BRCA2, exon 11 being essential, is
required for the regulation of BubR1 acetylation. However, we
do not exclude the possibility that the mutation of BRCA2 can
also affect indirect pathways leading to low score of BubR1
IHC in patients. Nevertheless, the result suggests that the score
of BubR1 IHC staining could reflect the status of BubR1 acetyla-
tion and the presence of BRCA2 mutations.
DISCUSSION
We have shown compelling lines of evidence that BRCA2 is
required for BubR1 acetylation in mitosis and, thus, is involved
in proper chromosome segregation. BRCA2 formed a complex
with BubR1 exclusively in mitosis (at prometaphase), suggesting
that this tumor suppressor evolved to manifest at least two
distinct functions in interphase and after chromosome conden-
sation: it is specialized to regulate DNA repair in interphase,
and after cells enter mitosis, it regulates BubR1 acetylation. In
yeast, BRCA2 is absent, and similarly, yeast Mad3 is not acety-
lated (Choi et al., 2009). This suggests that in metazoans, BubR1
acetylation may have evolved with the rise of BRCA2 for the
intactness of SAC and prevent from tumorigenesis.
BRCA2-BubR1 binding was specific to prometaphase and
was found in both the kinetochore and cytosol, as is BubR1.
Because BubR1 acetylation/deacetylation switches it from the
inhibitor to the substrate of APC/C-Cdc20, the finding that
BRCA2-BubR1 binding is also found in the cytosol fits with the
current idea (Malureanu et al., 2009). Nevertheless, the finding
that BRCA2 is found at prometaphase kinetochores with
BubR1 is important because unattached kinetochore generates
diffusible ‘‘wait anaphase signal’’ and also may be the site to
prolong SAC activation. Thus, it suggests an interesting possi-
bility that kinetochore-bound BRCA2may be involved in the sus-
tained SAC activation and signaling.(H) Percentage of cells displaying more than seven Rad51 foci before and after IR
antibody (Figure S5C). Numbers of cells analyzed are as follows: WT without IR
(n = 624). Data are from two independent experiments (mean ± SEM).
(I) Number of cells with chromatid breaks before and after IR (5 Gy). Values are t
(J) DR-GFP assay to compare HR efficiency in WT and mB2-9 MEFs. MEFs were
GFP-positive cells were analyzed by flow cytometry (see Figure S5D), and the p
experiments (mean ± SEM). See also Figure S5.
DevelopmIn interphase, BRCA2 is more likely to be regulating Rad51.
Therefore, it is likely that the Rad51-binding and BubR1-binding
form of BRCA2 differ, and that this is cell cycle regulated.
In this vein, the requirement of the middle portion (exon 11) of
BRCA2, which is not involved in binding to PCAF or BubR1,
suggests that the phosphorylation by mitotic kinases in the
middle part of BRCA2 may be essential for BRCA2 to function
in mitosis.
In humans, mutation of BubR1 causes a rare recessive
genetic disorder named mosaic variegated aneuploidy (MVA),
which manifests as growth retardation, microcephaly, childhood
cancer, and constitutional mosaicism for chromosomal gains
and losses (Hanks et al., 2004; Matsuura et al., 2006). Most
recently, gastrointestinal cancer was reported in an adult male
(Rio Frio et al., 2010), indicating that the accumulation of aneu-
ploidy caused by SAC disruption, particularly in the case of
BubR1 dysfunction, can induce tumorigenesis (Scully, 2010).
However, mice with low levels of BubR1 display premature aging
but do not develop spontaneous cancers on their own, although
the cells are aneuploidy (Baker et al., 2004). In mB2-9 the overall
level of BubR1 is intact: BubR1 level drops prematurely ‘‘in
mitosis’’ due to decrease of BubR1 acetylation, but not in inter-
phase. The nonacetylated BubR1 can form complex with Cdc20
as much as WT BubR1 can (Choi et al., 2009). Therefore, the
existence of nonacetylated BubR1 (together with acetylated
BubR1) in prometaphase weakens the SAC in mB2-9 mice. We
interpreted that the reason mB2-9 mice develop spontaneous
cancers while the mice with less BubR1 exhibit an aging pheno-
type is because nonacetylated BubR1 is able to form complexes
with APC/C-Cdc20 (and MCC, the mitotic checkpoint complex)
in mitosis and throughout the cell cycle, whereas hypomorphic
BubR1 mice fail to achieve adequate level of APC/C-Cdc20-
bound BubR1 complex formation.
Notably, the rare incidence of MVA suggests that BubR1 is
essential in embryogenesis as is in mice (Baker et al., 2004;
Wang et al., 2004); thus, inactivation of BubR1 as a first-hit muta-
tion would be rarer than expected. Therefore, any factor that
regulates BubR1 but is not an essential component of the SAC
may be a more common target for mutation in cancers. Here,
we present that BRCA2 may be one such target. We propose
that BRCA2 in SAC regulation may be like a fine-focus knob in
a microscope (Figure 6F).
Ectopic expression of the extreme C terminus of Brca2 in
mice resulted in perturbation of the normal Brca2-BubR1
binding. Unexpectedly, however, we observed no significant
increase in DNA damage. The checkpoint response to IR was
intact as well. Nonetheless, we do not exclude the possibility
that DNA damage can accumulate in tumorigenesis of mB2-9
mice. Given that early-passage MEFs exhibited a significant
increase in aneuploidy and malignant soft cell carcinoma dis-
played severe chromosome instability, it is reasonable to think(15 Gy). Cells were analyzed 6 hr post-IR with immunostaining with anti-Rad 51
(n = 893); mB2-9 without IR (n = 627); WT with IR (n = 1,158); mB2-9 with IR
he sum of three independent experiments.
cotransfected with 28 mg each of DR-GFP and I-SceI-expressing constructs.
ercentage was depicted as bar graphs. The result is from three independent
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Figure 6. BRCA2-Mutated Human Breast Cancers Display a Low
Level of BubR1, Compared with Cancers with WT BRCA2
(A–E) Breast cancer specimens were subjected to anti-BubR1 IHC and scored.
Five normal tissue samples were included and compared as a control (data
not shown). (A and B) Representative BubR1 IHC in cancer specimens with
WT BRCA2. (A) Representative normal ductal epithelial region (low IHC
expression,3400). (B) Invasive ductal carcinoma (high IHC expression,3400).
(C and D) BubR1 IHC in a cancer specimen with mutant BRCA2. (C) Normal
ductal epithelial region (low IHC expression, 3400). (D) Invasive ductal carci-
noma (low IHC expression, 3400). (E) Cumulative BubR1 scores for breast
cancer withmutantBRCA2 (n = 18) and breast cancer withWTBRCA2 (n = 24).
Correlation betweenBubR1 scores and expression of Ki-67 in 39 tumor tissues
is represented as a table (lower panel).
(F) A model for how BRCA2 participates in mitosis. As cells enter mitosis,
BRCA2 associates with BubR1 and helps the binding between PCAF and
BubR1. Without intact BRCA2, BubR1 acetylation is critically impaired, and
thus, the SAC activity is weakened. See also Table S1.
Developmental Cell
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decrease of BubR1 acetylation and weakened SAC. Thus,
mB2-9 mice in a way behaved as the mouse model that
dissected the mitotic role of BRCA2 from DNA repair. However,
we do not rule out the possibility that the ectopically expressed
B2-9 altered an unknown pathway and synergized with weak-
ened SAC. In comparison with mB2-9, mice deficient in exon
27 exhibit defective HR, senescence, and reduced life span
(Donoho et al., 2003; Morimatsu et al., 1998). Therefore, it is in-
terpreted that the consequences of losing the C terminus and
ectopically expressing it at a tolerable level (mB2-9 mice) are
different.306 Developmental Cell 22, 295–308, February 14, 2012 ª2012 ElsevOur analysis of human breast cancers suggests that the
BRCA2-BubR1 connection might have clinical implications
in the development of prognostic factors and the choice of
adequate therapies. For example, IHC analysis of BubR1 may
be informative for the choice of adequate treatment of breast
cancers related to the status of BRCA2, and the development
of inhibitors that specifically interfere with BubR1 deacetylation
may be useful for the treatment of BRCA2-mutated cancers.
EXPERIMENTAL PROCEDURES
Statistical Analysis
SPSS software was used for statistical analyses. Student’s t test was used
unless otherwise stated. Mean ± SEM is shown wherever required.
Purification of Recombinant Proteins and In Vitro AcetylationAssays
For the purification of proteins from E. coli, BubR1 (DBR2, amino acids 1–514),
B2-9 (BRCA2 C terminus), BRCA2 (B2-N1, amino acids 1–500), BRCA2
(B2-N2, amino acids 290–453), and PCAF (amino acids 352–832) were subcl-
oned into pGEX 4T-1 (Amersham) and purified as GST-fusion proteins. In addi-
tion the BubR1 deletion mutant DBR1-5 was subcloned into pGEX 4T-1. The
indicated combinations of recombinant proteins were incubated for 1 hr at
30C in HAT buffer (250 mM Tris-HCl [pH 8.0], 50% glycerol, 0.5 mM EDTA,
5 mM dithiothreitol, and 1 mM unlabeled acetyl-coenzyme A). Proteins were
separated by SDS-PAGE and analyzed by WB using an anti-acetyl lysine
antibody.
Cell Culture and Synchronization at Prometaphase
HeLa cells were cultured in DMEM supplemented with 10% v/v FBS. HeLa
cells stably expressing FLAP-targeted BRCA2 were cultured in medium sup-
plemented with 400 mg/ml G418 (Lekomtsev et al., 2010).
To synchronize HeLa cells at prometaphase, cells were treated with thymi-
dine (2mM) for 16–20 hr, released for 6 hr, treatedwith 100 ng/ml Noc for 13 hr,
and then collected by mitotic shake off.
To synchronize MEFs at prometaphase, cells were cultured in DMEM sup-
plemented with 0.1% v/v FBS for 14 hr, followed by culture in DMEM supple-
mented with 20% v/v FBS for 7 hr. The cells were then treated with 250 ng/ml
of Noc for 7 hr.
To synchronize mouse splenocytes, cells were cultured in RPMI supple-
mented with 10% v/v FBS in the presence of PMA (500 ng/ml), Ionomycin
(500 ng/ml), and LPS (10 mg/ml) for 36 hr. The cells were then treated with
250 ng/ml of Noc for an additional 7 hr.
Immunofluorescence Microscopy
Immunofluorescent images (Choi et al., 2009; Choi and Lee, 2008) were
acquired using a CoolSnap HQ cooled CCD camera on a DeltaVision Spectris
Restoration microscope built around an Olympus IX70 stand (Applied Preci-
sion). Images were acquired as a series of 0.4-mm-thick image sections and
deconvolved using the iterative algorithm implemented in softWoRx software
(Applied Precision).
Time-Lapse Video Microscopy
MEFs were transfected with the pSV40-mRFP-H2B expression plasmid and
grown in 35 mm Delta-T dishes (Bioptechs), with or without 200 ng/ml Noc
during the recording. Time-lapse images were obtained using DeltaVision
(Applied Precision) every 5 or 10 min.
Cell-Cycle Analysis after Depletion of BRCA2
HeLa cells were transfected twice with siRNA against control or BRCA2 in
24 hr intervals. Forty-eight hours post-second siRNA transfection, cells were
pulsed with 10 mM BrdU for 1 hr then fixed in cold 70% ethanol. DNA was
denatured with 3 N HCl and stained with FITC-anti-BrdU antibody and propi-
dium iodide. In case of Brca2 conditional knockout MEFs, analysis was done
36–48 hr post-adenoviral infection, expressing GFP or Cre. We used FACS-
Canto (Becton Dickinson) for flow cytometry, and the analysis was done
with CellQuest software.ier Inc.
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Pulse-Chase
For BrdU labeling, cells were labeled with 10 mM BrdU for 2.5 hr, then washed
and incubated in Noc containing medium for indicated time points, and fixed
with cold methanol. DNA was denatured with 3 N HCl for 10 min at room
temperature. The cells were washed and subjected to double immunostaining
with anti-BrdU and anti-pH3 antibodies.
IHC and Scoring BubR1 IHC in Paraffin Sections of Tissues
from Patients with Breast Cancer
Pathology samples from 42 patients and 5 samples of normal breast tissue
distant from tumors were obtained as paraffin-embedded samples from the
Seoul National University Hospital. The samples were collected according to
the research protocol approved by the Institutional Review Board (H-1103-
159-357). Of the 42 patients, 18 had hereditary breast cancer with a deleterious
germline mutation of BRCA2, and 24 had sporadic breast cancer without
a BRCA2 mutation. BRCA2 mutations were confirmed by gene sequencing.
BubR1 scores in human cancer tissueswere determined by IHC on 4 mm tissue
sections.
The percentage of positive staining distribution was recorded and scored as
follows: a score of 0 (zero) for staining of <5%, 1 for 6%–30% staining, 2 for
30%–70% staining, and 3 for staining of >70%. The staining intensity was
scored as follows: a score of 0 (zero) for absent tumor cell staining, 1 for
weak staining (equivocal to normal epithelium), 2 for moderate staining, and
3 for strong staining. The results for intensity and distribution were summed,
and total score was assigned as follows: 0–3, low expression of BubR1; 4–6,
high expression of BubR1. Statistical analysis was carried out using nonpara-
metric tests. Mann-Whitney U statistical analysis was used to compare differ-
ences in BubR1 scores between patients with a BRCA2 mutation and those
without. Cancer diagnosis and analysis were performed by pathologists
from Asan Medical center (G. Gong) and Seoul National University Hospital
(H. Lee).
Animal Care
Mice were housed in a semi-conventional (virus antibody-free) facility. All
mouse experiments were approved by the Institutional Animal Care and Use
Committee of Seoul National University. We strictly followed the Seoul
National University guidelines, policies, and regulations for the Care and Use
of Laboratory Animals.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, Supplemental
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